---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034263"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:17:08.779305+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech Enters Research Agreement with UNC to Evaluate Annamycin for Pancreatic Cancer

## Summary
- Agreement with University of North Carolina at Chapel Hill for investigator-initiated preclinical research on Annamycin for pancreatic cancer.
- Moleculin will supply Annamycin; studies will evaluate liposomal Annamycin vs. Doxil in PDAC GEMM models.
- CEO Walter Klemp noted Annamycin's high affinity for pancreas and correlation of topoisomerase II upregulation with poor survival.
- Preclinical research is grant-funded and dovetails with recently announced investigator-funded clinical trial in pancreatic cancer patients.
- Annamycin has Fast Track Status and Orphan Drug Designations from FDA for AML and STS lung mets, and EMA for relapsed/refractory AML.

## SEC filing metadata
- accession: 0001437749-25-034263
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/0001437749-25-034263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925034263/mbrx20251110_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034263
- JSON: https://secwatch.observer/filing/0001437749-25-034263.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.